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Objective: Inhibition of cyclooxygenase 2 provides analgesia in ambulatory pa-
tients. We prospectively evaluated the safety and efficacy of a newly introduced
cyclooxygenase 2 inhibitor in patients undergoing coronary artery bypass grafting
surgery through a median sternotomy in a randomized clinical trial.
Methods: A total of 462 patients with New York Heart Association classes I to III
who were less than 77 years of age and were from 58 institutions in the United
States, Canada, Germany, and the United Kingdom participated in this multicenter,
phase III, placebo-controlled, double-blind, randomized, parallel-group trial. Pa-
tients were allocated at a ratio of 2:1 to parecoxib/valdecoxib or standard care
(control) groups, respectively. Intravenous study drug (40 mg) was administered
within 30 minutes after extubation and every 12 hours for a minimum of 3 days.
Subsequently, oral treatment at a dose of 40 mg every 12 hours was initiated and
administered for a combined total of 14 days. Patient-controlled analgesia with
morphine, oral opioids, or acetaminophen was available as required. Assessment of
the analgesic efficacy of the study drug was primarily based on morphine and
morphine equivalent use. Additional efficacy evaluations included daily pain inten-
sity, patient and physician global evaluation of study medication, and pain effect on
quality of life. Clinical adverse events were assessed by the principal investigator at
each site from the time of the first dose through the 30-day postdosing period.
Results: Patients in the parecoxib/valdecoxib group received significantly less
morphine or morphine equivalents than patients in the control group during the 0-
to 24-hour (P  .009), 24- to 48-hour (P  .017), 72- to 96-hour (P  .002), 96-
to 120-hour (P  .004), and 120- to 144-hour (P  .037) periods. Both patients
(P  .001) and physicians (P  .001) evaluated the study medication as signifi-
cantly better than control therapy. The modified Brief Pain Inventory questionnaire
used in the oral dosing period detected significant improvements in the parecoxib/
valdecoxib treatment group in 6 of 8 domains tested (eg, current pain, worst pain,
and mood) beginning on day 4 and continuing for at least 4 days. Although there
were no differences between the groups in overall adverse events, serious adverse
events occurred twice as frequently in parecoxib/valdecoxib-treated patients
(19.0%, 59/311 patients) than in control patients (9.9%, 15/151 patients; P  .015).
Regarding individual serious adverse events, a greater incidence in sternal wound
infection was found in the parecoxib/valdecoxib patients (10 [3.2%]) versus control
patients (0 [0%]) (P  .035). The incidences of other individual serious adverse
events, including cerebrovascular complications, myocardial infarction, and renal
dysfunction, were proportionally greater but not significantly different between the
groups.
Conclusions: In patients undergoing coronary artery bypass grafting surgery, the
cyclooxygenase 2 inhibitor combination, parecoxib/valdecoxib, was effective for
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postoperative analgesia. However, the 14-day treatment regimen also was associated
with an increased incidence of serious adverse events overall and sternal wound
infections in particular. Therefore our study raises important concerns requiring
their comprehensive evaluation in a large-scale trial before these cyclooxygenase 2
inhibitors are used in patients undergoing coronary artery bypass grafting surgery.
After coronary artery bypass grafting(CABG), patients experience incisionalpain associated with sternotomy, chesttube insertion, and leg vein excision.1Opioids and nonsteroidal anti-inflamma-tory drugs (NSAIDs) are administered
parenterally as analgesics in the early postoperative period
to alleviate such pain.2 However, the efficacy of these
analgesic drugs is limited by side effects that impede patient
rehabilitation after surgical intervention. Opioids, such as
morphine sulfate, can be associated, particularly in older
patients, with respiratory depression, excessive sedation,
and confusion, and parenteral NSAIDs, such as ketorolac,
can be associated with gastrointestinal ulceration, renal dys-
function, and bleeding caused by platelet inhibition.3 There-
fore development of new analgesics that are not only effi-
cacious but also have an improved side-effect profile would
enhance patient comfort and well-being and even reduce
resource use costs.
In ambulatory patients and general surgical patients,
among the newest approaches to acute pain control is se-
lective inhibition of the cyclooxygenase 2 (COX-2) en-
zyme, which mediates inflammatory prostaglandin synthe-
sis.4-6 Inhibiting the inducible COX-2 isoform results in
desirable anti-inflammatory and analgesic effects, whereas
nonselective inhibition of the constitutive COX-1 and
COX-2 enzymes is associated with gastrointestinal, platelet-
related, renal, and other adverse side effects.7 Conventional
NSAIDs nonspecifically inhibit both COX isoforms.8-11
Higher-risk populations have not been specifically stud-
ied in prior selective COX-2 inhibitor analgesia clinical
trials, resulting in limited experience with efficacy and
safety in these populations. Therefore we prospectively
studied patients undergoing CABG surgery by using a new
parenteral combined with oral COX-2 selective inhibitor.
Methods
General Study Design
This was a multicenter, double-blind, and controlled clinical trial,
with the active study medication (parecoxib/valdecoxib) or stan-
dard care (control) randomized in a 2:1 ratio within each center.
After institutional approval and written informed consent were
obtained, 462 patients undergoing CABG were enrolled from 58
medical centers in the United States, Canada, Germany, and the
United Kingdom between January and May 2000.
Preoperative inclusion criteria were age of less than 77 years,
body mass index (BMI) of less than or equal to 40 kg/m2, weight
of greater than 55 kg, left ventricular ejection fraction of greater
than or equal to 35%, and New York Heart Association class of I
to III. In addition, in each patient the presence of adequately
treated blood pressure and absence of psychologic illness were
confirmed. Exclusion criteria were patients undergoing emergency
surgery and those with a recent (48 hours) myocardial infarction,
insulin-dependent or uncontrolled diabetes (fasting blood sugar
350 mg/dL or 19.4 mmol/L), increased concentrations of liver
enzymes (aspartate aminotransferase or alanine aminotransferase
1.5 of the upper limit of normal), creatinine level of greater than
1.5 mg/dL (or 133 mol/L), or any coagulopathy. Also excluded
were patients with stroke or transient ischemic attack within 6
months and those with substance abuse (opioids, any other anal-
gesics, or alcohol), allergy to nonsteroidal anti-inflammatory
agents, or a history of gastric or duodenal ulcer.
Intraoperative exclusion criteria included a complicated intra-
operative course, cardiopulmonary bypass time exceeding 3 hours,
or insertion of an intra-aortic balloon pump. In the postoperative
period and before randomization, patients were excluded from the
study if they were receiving 3 or more inotropic infusions, had a
symptomatic dysrhythmia, had new Q-wave myocardial infarction,
had a cardiac index of less than 1.5 L/min, had a chest tube output
of greater than 500 mL in a 2-hour period, had a temperature of
less than 36°C or greater than 38°C, had a urine output of less than
50 mL/h, had a hemoglobin level of less than 8 g/dL (or 1.24
mmol/L), or had a serum creatinine level exceeding 1.2 mg/dL (or
106 mol/L) or 30% greater than the baseline value.
Study Procedures Before Drug Administration
Preoperative cardiac medications were continued until the time of
surgical intervention. Anesthesia was induced by using fentanyl
and/or midazolam, isoflurane, and a muscle relaxant for tracheal
intubation. Anesthesia was maintained with isoflurane and/or
propofol, fentanyl, midazolam and pancuronium in all institutions.
Although the conduct of the anesthesia and surgical intervention
was similar for each institution, no attempts were made to further
standardize techniques. Cardiopulmonary bypass was used in 89%
(411/462) of patients with hemodilution, mild-to-moderate hypo-
thermia, and membrane oxygenators, with no difference between
groups. In 11% (51/462) of patients, off-pump CABG was per-
formed. For initial management in the intensive care unit, propo-
fol, morphine, or midazolam for sedation and analgesia were
administered at the discretion of the treating clinician. All patients
in both study groups received aspirin (80-325 mg/d), starting by
the time of the first dose of study medication. In each patient the
trachea was extubated within 15 hours of surgical intervention.
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Subsequently, those meeting the inclusion and exclusion criteria
were randomized.
Administration of Parecoxib/Valdecoxib
Intravenous administration of the study drug (40 mg of parecoxib
or placebo) began within 30 minutes of extubation of the trachea
immediately after a baseline pain assessment but before initiation
of patient-controlled analgesia (PCA). The study drug was then
administered intravenously every 12 hours and was continued for
a minimum of 72 hours to allow uniform assessment of efficacy
and safety over the first 3 days among all participating centers. All
patients had access to intravenous morphine sulfate by means of
PCA for supplemental pain medication starting immediately after
tracheal extubation and continuing for at least 24 hours and there-
after at the discretion of the treating clinician. In addition to
study-mandated treatments, all other medications required to man-
age a patient’s individual care were permitted, with the exception
of NSAIDs.
After 72 hours, if the patient were able to tolerate oral medi-
cation, the intravenous dosing scheme was changed to an enteral
(oral) scheme, at which time either 40 mg of valdecoxib or placebo
was administered every 12 hours. Supplemental pain medication
consisting of combinations of codeine (30 mg) and acetaminophen
(300 mg or 500 mg) in doses of 1 to 2 tablets every 4 to 6 hours
was available to all patients and administered at their discretion. At
the time of discharge from the hospital, each patient received the
oral study medication and supplementary pain medication, with
instructions to continue study-mandated treatment after hospital-
ization. The oral dosing period was scheduled to last from the end
of intravenous dosing to day 14.
Evaluation of Analgesic Efficacy
The primary measure for comparing efficacy of parecoxib/valde-
coxib versus control was the amount of morphine sulfate (or
morphine equivalents consumed).12-14 Additional assessments in-
cluded a daily pain intensity score recorded as peak intensity on a
4-point categoric scale. A clinical investigator evaluated pain
intensity daily for each day of treatment. Also, the peak pain
intensity difference between maximum daily sternotomy pain and
pretreatment sternotomy pain was calculated for each day of
treatment.
At the time of transition from intravenous to oral drug admin-
istration, before hospital discharge, and on day 14 (study termina-
tion or sooner if premature termination occurred), physician and
patient global assessments of the effects of the study medications
were obtained. On discharge from the hospital, each patient re-
ceived a patient diary to continue daily pain assessments. The diary
included the modified Brief Pain Inventory, a validated instrument
designed to evaluate the effect of pain on the patient’s ability to
perform daily living activities.
Safety Assessment
Safety was assessed on the basis of the occurrence of clinical
adverse events (AEs) and serious adverse events (SAEs), as re-
ported by the principal investigator at each site. AEs were judged
to be serious if they resulted in a fatality or hospitalization or if the
principal investigator believed that the event was life threatening
or otherwise medically significant. The principal investigator at
each study site also made a judgment as to whether there was a
probable, uncertain, or lack of relationship of each AE to study
treatment. When multiple episodes of the same AE were reported,
the greatest known attribution was presented. All events occurring
from the time of the first dose through the 30-day postdosing
period were included. The World Health Organization Adverse
Reaction Terminology dictionary15 was used to code the investi-
gator’s description of AEs, and the resulting primary terms were
used in the calculation of incidence for comparative analysis. In
addition to AE assessment, safety was evaluated on the basis of
physical examination, measurement of vital signs, recording of
electrocardiographs, and collection of blood samples for clinical
laboratory measurements at the time of changing from intravenous
to oral drug administration, before hospital discharge, and on day
14 (study termination or sooner if premature termination oc-
curred).
Statistical Analysis
Efficacy. The proportion of patients who received opioids,
including morphine PCA, during fixed time intervals was com-
pared between treatment groups by using the Cochran-Mantel-
Haenszel test stratified by country. Mean morphine consumption
by means of PCA and total opioid (morphine equivalents) con-
sumption were compared on the basis of time intervals by using an
analysis of variance (ANOVA) with treatment and country as
factors and with the time to first morphine dose as an additional
factor when appropriate. Oral opioid use per day was recorded and
compared between treatment groups by using a Wilcoxon test. No
assumption was made for missing values in the primary efficacy
variable (morphine consumption). Peak pain intensity difference
was analyzed by using an ANOVA with treatment and country as
factors and baseline pain intensity as a covariate. Except for the
primary efficacy variable (morphine consumption), the approach
of last observation carried forward was adopted to account for
missing values. When multiple time periods were combined for
presentation, the largest P value among the combined periods was
reported. The patient’s and the physician’s global evaluations of
study medication at the time of transition from intravenous to oral
administration, discharge from the hospital, and final visit were
compared between treatment groups by using the Cochran-Mantel-
Haenszel test stratified by country.
Safety. The incidences of both AEs and SAEs were compared
between treatment groups by using the Fisher exact test, which
provides a P value for each comparison. Multiple logistic regres-
sion was used to evaluate potential risk factors for SAEs. The
changes from baseline values in laboratory tests and vital signs
were compared between treatment groups with a 1-way ANOVA.
The intent-to-treat cohort was used in all safety and efficacy
analyses of morphine consumption. The intent-to-treat cohort con-
sisted of all patients who received a dose of study medication, a
total of 462 patients (311 patients in the parecoxib/valdecoxib
group and 151 patients in the control group).
Treatment group assignment and power. Patients were ran-
domized to one of the 2 treatment groups in a ratio of 2:1 for
parecoxib/valdecoxib versus control treatment. The sample sizes
of 300 patients in the group receiving intravenous 40 mg of
parecoxib/oral 40 mg of valdecoxib and 150 patients receiving
placebo were sufficient to detect a minimum difference of 12 mg
Ott et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1483
CS
P
in the average consumption of morphine between the 2 groups by
using a 2-sided test at a 5% level of significance with 85% power.
These sample sizes were sufficient to detect at least one occurrence
of AEs of 1% incidence in the treatment group and 2% in the
control group with 95% confidence and to compare individual AE
rates of 1% versus 7% by using a 2-sided test at a 5% level of
significance with 80% power.
Results
Characteristics of the Patients
Between January 2000 and May 2000, 462 patients were
enrolled and randomized to receive parecoxib/valdecoxib
(311 patients) or standard therapy (control group, 151 pa-
tients). The population ranged in age from 34 to 76 years,
with a mean age of 60.3 and 61.3 years in the parecoxib/
valdecoxib group (P/V group) and the control group, re-
spectively (Table 1). Thirty-three percent of patients in the
P/V group and 38% of control patients were 65 years of age
or older. There was no substantial difference between the
preoperative characteristics or study group assignment
among those patients who underwent surgical intervention
with cardiopulmonary bypass versus those without cardio-
pulmonary bypass (Table 1). Except for a BMI of greater
than 30 kg/m2 (P  .037) and a trend toward increased
prevalence of peripheral vascular disease (P  .097) in the
P/V group (Tables 1 and 2), the proportion of patients with
cardiac disease-related risk factors was similar between the
P/V and control groups (Table 2).
Of the 462 patients randomized to receive study medi-
cation, 26% (118 patients) were withdrawn from the study
after receiving at least one dose of study drug: 27% (84
patients) from the P/V group and 23% (34 patients) from the
control group. The most frequent reasons for early with-
drawal overall were AEs (15.6%, 72 patients), protocol
noncompliance (7.8%, 36 patients), treatment failure (1.1%,
5 patients), and protocol violations (0.9%, 4 patients). Pa-
tients were observed for a mean of 12.5  4.8 days. During
the intravenous dosing period, patients in both treatment
groups received an average of 6.6 doses. During the oral
dosing period, patients in both groups received an average
of 19.7 doses administered every 12 hours.
Efficacy
Primary efficacy measure: Morphine consumption.
Morphine consumption by means of PCA after the initial
administration of study medication was assessed during
each 24-hour interval. The amount of morphine PCA used
by patients in the P/V group was significantly less than that
in the control group for the periods from 0 to 24 hours (P 
.015), 24 to 48 hours (P  .020), and 72 to 96 hours (P 
.023). Total morphine and total opioid (morphine equiva-
lent) consumption at 24 hours was approximately 23% less
in the P/V group relative to the control group for morphine
PCA (P  .009, Table 3). In addition, significant cumula-
tive reductions (approximately 20% relative to control, P 
0.039) were seen at 72 hours. By the 96- to 120-hour
interval, only 3 patients were receiving morphine PCA.
Supportive efficacy measures. The mean peak pain in-
tensity difference was significantly greater, indicating
greater pain relief for COX-2 inhibitor treatment compared
with control treatment on days 1 to 9 (P  .015, Figure 1).
A significantly greater (P  .001) proportion of patients in
the P/V group rated the study medication as good or excel-
lent (88%-91%) compared with control ratings of good or
excellent (71%-78%) at all assessment periods, at intrave-
nous to oral transition, at discharge from the hospital, and at
the patient’s final visit. Similarly, a greater proportion (P 
.001) of physicians rated parecoxib/valdecoxib treatment as
good or excellent (88%-90%) compared with control treat-
ment (69%-74%) at each of the same assessment periods,
and a smaller proportion (P  .001) of physicians rated
parecoxib/valdecoxib treatment as poor (2%) compared
with control treatment (13%). As measured by the modified
Brief Pain Inventory questionnaire, during oral therapy,
there were significant reductions with parecoxib/valdecoxib
treatment compared with control treatment in current pain
(days 4-7), worst pain (days 4-9), average pain (days 4-8),
mood (days 4-12), relations with others (days 4-12), sleep-
ing (days 4, 5, 7, and 8), and walking (days 4 and 5).
Safety
Adverse events. AEs were reported in 89.4% (135/151
patients) of control and 89.1% (277/31 patients) of P/V
group patients during the study period (P  .95, Table 4).
TABLE 1. Demographics of each treatment group
Standard
of care,
n  151 (%)
Parecoxib/valdecoxib 40
mg IV/PO Q12H,
n  311 (%) P value
Age (y) .223*
Mean  SD 61.3 8.0 60.3 8.2
Range 41-75 34-76
Sex
Male 135 (89) 265 (85) .215†
Female 16 (11) 46 (15)
Country .998†
United States 56 (37) 114 (37)
United Kingdom 14 (9) 30 (10)
Canada 41 (27) 83 (27)
Germany 40 (26) 84 (27)
BMI .037†
30 112 (75) 203 (65)
30 38 (25) 108 (35)
% Off pump 21 (14) 30 (10) .21
IV, Intravenous; PO, oral; Q12H, every 12 hours.
*ANOVA with treatment group and country as factors.
†2 test.
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Pleural effusions, fever, bronchospasm, and tachycardia
were seen with higher frequency in control patients,
whereas supraventricular tachycardia and hypotension oc-
curred more often in P/V group patients. AEs led to study
withdrawal of 13.2% (20 patients) control and 16.7% (5
patients) P/V group patients (P  .412). Nausea (2.0% of
control and 2.6% of P/V group patients, P  .95) and
vomiting (2.0% of control and 1.6% of P/V group patients,
P  .720), followed by a creatinine increase (1.3% of
control and 1.9% of P/V group patients, P  .95), were the
most common individual events that led to withdrawal from
the study. Abnormalities in laboratory tests were common
in both treatment groups but similar between groups. The
incidence of renal dysfunction (as defined by a creatinine
value 2.0 mg/dL [177 mol/L] and an increase of 0.7
mg/dL [0.62 mol/L] from baseline16) was 2.6% in both
groups (P/V group, 8 patients; control group, 4 patients).
Similar proportions (P  .512) of patients in the P/V group
(29.6%) versus the control group (26.5%) received blood
products, with mean transfusion requirements not differing
(P  .398) between groups (2.30 units per patient vs 2.55
units per patient, respectively).
TABLE 3. Amount of total opioid (morphine equivalents) consumed during fixed time intervals in each treatment group
Time interval (h)
Standard of care, n  151 (mg)
Parecoxib/valdecoxib 40 mg IV/PO
Q12H, n  311 (mg)
P valuen Mean SD n Mean SD
0-24 123 25.4 24.3 251 19.7 18.7 .009
24-48 135 31.8 28.0 264 25.1 23.8 .017
48-72 98 16.5 17.4 177 14.0 18.2 .260
72-96 78 12.3 15.4 124 7.5 6.4 .002
96-120 62 7.7 6.2 101 5.5 3.4 .004
120-144 59 6.2 5.1 93 5.1 3.5 .037
144-168 53 6.7 4.0 79 5.6 4.0 .098
P value was determined by means of 2-way ANOVA, with treatment and country as factors. IV, Intravenous; PO, oral; Q12H, every 12 hours.
TABLE 2. Patient characteristics of each treatment group
Condition
Standard of care,
n  151 (%)
Parecoxib/valdecoxib 40 mg
IV/PO Q12H, n  311 (%) P value*
Angina .700
Current 95 (63) 196 (63)
History 45 (30) 86 (28)
Hypertension .295
Current 100 (66) 184 (59)
History 17 (11) 38 (12)
Congestive heart failure .619
Current 4 (3) 6 (2)
History 2 (1) 8 (3)
Atherosclerotic CVD .457
Current 121 (80) 248 (80)
History 5 (3) 18 (6)
Myocardial infarction .685
Current 3 (2) 10 (3)
History 66 (44) 128 (41)
Cerebrovascular ischemia .595
Current 0 (0) 0 (0)
History 7 (5) 18 (6)
Peripheral vascular disease 45 (30) 117 (38) .097
Diabetes mellitus .746
Current 29 (19) 69 (22)
History 1 (1) 2 (1)
Tobacco use .538
Current 19 (13) 51 (17)
History 85 (56) 168 (54)
IV, Intravenous; PO, oral; Q12H, every 12 hours; CVD, Cardiovascular disease.
*Cochran-Mantel-Haenszel test stratified by country.
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Serious adverse events. The overall incidence of SAEs
was 19% (116 events in 59 patients) in the P/V group
compared with 9.9% (26 events in 15 patients) in the control
group (P  .015, Table 5).
Four deaths occurred in the P/V group versus zero in the
control group (P .309). The causes of death were reported
as myocardial infarction, cerebral infarction, pulmonary
thromboembolism, and sternal wound infection.
Sternal wound infections occurred in 10 (3.2%) P/V
group patients versus zero patients in the control group (P
.035). These were characterized by the investigators as 5
sternal wound infections, 2 deep sternal wound infections, 2
superficial sternal wound infections, and 1 sternal wound
dehiscence caused by infection. Other than parecoxib/valde-
coxib use, no other risk factor (eg, body mass) was associ-
ated with sternal wound infection.
Myocardial infarction was reported as an SAE in 1.6%
(5/311) of P/V group patients versus 0.7% (1/151) of control
patients (P  .669). Four of the 5 myocardial infarctions in
the P/V group patients were given a diagnosis in the imme-
diate perioperative period (within 24 hours of surgical in-
tervention), whereas the other fifth occurred 14 days after
the last dose of study medication.
Cerebrovascular complications occurred in 9 (2.9%) P/V
group patients versus 1 (0.7%) patient in the control group
(P  .177). Risk factors significantly associated with oc-
currence of a cerebrovascular complication by means of
stepwise logistic regression analysis included age of greater
than 65 years (odds ratio  8.15), BMI of greater than 30
kg/m2 (odds ratio  7.18), and history of cerebrovascular
disease (odds ratio  16.62).
Renal events occurred in 6 (1.9%) P/V group patients
versus zero patients in the standard care group (P  .184).
None of these events required treatment with dialysis. Among
P/V group patients, a history of diabetes was significantly
associated with development of a renal event (P  .017).
Figure 1. Peak pain intensity difference is defined as the reduction of peak pain intensity from baseline values.
Higher values of peak pain intensity difference indicate less pain. *P < .050 for analysis of covariance with
treatment and country as factors and baseline pain intnsity as covariate.
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Relationship to Study Medication
Of the 116 events in the P/V group, 97 events were classi-
fied as not related to the study drug by the investigator, 19
were classified as having an uncertain relationship to the
study drug, and 1 (renal function abnormality) was classi-
fied as probably related to the study drug. Regarding the
control group, of the 26 events, 24 were classified as not
related to the study drug, 2 as having an uncertain relation-
ship to the study drug, and none as having a probable
relationship to the study drug.
Discussion
CABG Surgery and COX-2 Inhibition
A number of factors, including the preoperative chronic
disease state, the quality of anastamoses, the effectiveness
of myocardial preservation, increased patient age, sex, and
the need for emergency surgical intervention explain the
serious morbidity after CABG surgery.16-18 Over the past
several decades, significant gains in the management of
patients undergoing coronary artery surgery have been
achieved through improved intraoperative monitoring, myo-
cardial preservation, and surgical technique. Advances have
also been made in the area of pain control drugs. These
include a variety of techniques (spinal opioids and local
anesthetics) and drugs (natural and synthetic opioids, seda-
tive-hypnotics, 2-adrenergic agonists, and NSAIDs). Ide-
ally, these therapies provide not only patient comfort but
also mitigation of untoward cardiovascular responses (hy-
pertension, tachycardia, and myocardial ischemia), pulmo-
nary responses (shunting and splinting), and other inflam-
matory and secondary sympathetic responses.2
However, as the age of patients undergoing CABG sur-
gery increases, the prevalence of comorbid conditions will
increase, and therefore therapies demonstrating reductions
in untoward side effects will be desirable. Such therapies
should facilitate early discharge or at least limit prolonged
hospitalization for this population. Early ambulation is crit-
ical and will require more complete pain relief while pre-
serving cognition.19 Use of opioids or sedatives-hypnotics
will necessarily have to be limited. The use of NSAIDs,
which profoundly affect the pain response yet have little
effect on the sensorium (sedation, confusion, and disorien-
tation), has been a major advance in the postoperative care
of these patients. However, although effective, the initially
developed nonselective NSAIDs (eg, ketorolac
tromethamine [INN: ketorolac]) are associated with gastro-
intestinal ulceration and bleeding, antiplatelet effects, renal
dysfunction,3,8-11 and, more recently, congestive heart fail-
ure, the latter of which was found to be more prevalent and
severe in older patients.20-23 Nonetheless, despite these
drawbacks, nonsteroidal anti-inflammatory agents have
been recently studied for brief periods (48 hours) in
managing postoperative pain after cardiac surgery.24-26
However, other novel approaches have been sought, with
the most recent being the selective inhibition of the COX-2
enzyme, thereby blocking inflammatory prostaglandin syn-
TABLE 4. AEs: Events occurring in at least 10% of patients
in either treatment group or for which there was a differ-
ence (P < .100) between groups
Adverse event
Standard




n  311 (%) P value
Abnormal breath sounds 21 (13.9) 44 (14.1) .95
Atrial fibrillation 30 (19.9) 49 (15.8) .293
Bronchospasm 10 (6.6) 6 (1.9) .014
Constipation 56 (37.1) 116 (37.3) .95
Dizziness 27 (17.9) 37 (11.9) .086
Peripheral edema 21 (13.9) 51 (16.4) .585
Fatigue 31 (20.5) 57 (18.3) .614
Fever 32 (21.2) 13 (4.2) .001
Hypotension 9 (6.0) 41 (13.2) .024
Insomnia 23 (15.2) 59 (19.0) .365
Nausea 58 (38.4) 138 (44.4) .230
Oliguria 15 (9.9) 45 (14.5) .187
Pleural effusion 26 (17.2) 27 (8.7) .002
Red blood cell disorders 11 (7.3) 36 (11.6) .190
Somnolence 19 (12.6) 36 (11.6) .761
SVT 0 (0.0) 10 (3.2) .035
Tachycardia 22 (14.6) 22 (7.1) .017
Vomiting 17 (11.3) 43 (13.8) .466
Anxiety 14 (9.3) 15 (4.8) .060
Rash 4 (2.6) 2 (0.6) .092
P value was determined with the Fisher exact test. SVT, Supraventricular
tachycardia.
TABLE 5. SAEs occurring in more than 2 patients in either
group
Standard care,




n  311 (%) P value*
Any SAE 15 (9.9) 59 (19.0) .015
Death 0 4 (1.3) .309
Cerebrovascular disorder 1 (0.7) 9 (2.9) .177
Myocardial infarction 1 (0.7) 5 (1.6) .669




0 6 (1.9) .184
Gastrointestinal
hemorrhage
0 3 (1.0) .554
Pleural effusion 1 (0.7) 7 (2.3) .283
Pneumonia 3 (2.0) 4 (1.3) .688
Sternal wound infection 0 10 (3.2)† .035
Thrombophlebitis 0 3 (1.0) .554
*Fisher exact test.
†Includes 5 sternal wound infections, 2 deep sternal wound infections, 2
superficial sternal wound infections, and 1 sternal wound dehiscence
caused by infection.
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thesis. The inducible form of this enzyme provides both
analgesic and anti-inflammatory effects when inhibit-
ed.7,23,27 In contrast, inhibition of the constitutive COX-1
enzyme is associated with gastrointestinal, renal, and bleed-
ing side effects. Because the efficacy of the COX-2 inhib-
itors celecoxib and rofecoxib, as well as parecoxib/valde-
coxib, has been demonstrated in patients undergoing
general surgery, we assessed the latter in higher-risk pa-
tients (ie, those with coronary artery disease undergoing
revascularization). If effective and safe, then NSAID-asso-
ciated gastrointestinal and platelet-associated complications
might be circumvented, and other benefits might be gained
by means of mitigation of the reperfusion-associated in-
flammatory response.
Because untoward pain responses after CABG surgery
might last for several days, a COX-2 agent that could be
administered both intravenously and orally was appealing.
Efficacy Findings
Our study was designed to compare a novel COX-2 inhib-
itor regimen (ie, intravenous parecoxib, followed by oral
valdecoxib) to a control regimen that included PCA. Al-
though a number of centers typically use a less-aggressive
approach to pain control, we believed that such a stringent
standard for the control group was appropriate because any
new therapy should have efficacy exceeding that of the most
aggressive pain control regimens.2 We found a statistically
significant reduction in morphine PCA use in the P/V group
for periods from 0 to 24 hours, 24 to 48 hours, and 72 to 96
hours. These findings were supported by the consistent
reductions in the amount of total opioids consumed for each
24-hour period up to 168 hours, patient’s perception of pain,
physician’s global assessment, and improvement in pain-
related quality of life.
Safety Findings
Regarding safety, however, we found several results that
raised concern. First, although the overall incidence of AEs
was comparable in the 2 groups, significantly more patients
in the P/V group had SAEs than in the control group (P 
.015). Of specific concern is that the incidence of sternal
wound infections was significantly greater in the P/V group
patients compared with that in control subjects (10/311 vs
0/151, P  .035). The effects of NSAIDS on sternal wound
complications in the CABG surgical setting have not been
previously reported. The COX-2 enzyme enables prosta-
glandin release and inflammatory response, and inhibition
of this enzyme by nonspecific COX inhibitors (eg,
NSAIDs), as well as specific COX-2 inhibitors (eg, pare-
coxib and valdecoxib), might impede reparative inflamma-
tory responses and increase susceptibility to sternum infec-
tions. An alternative hypothesis is that the reduced rates for
fever and tachycardia among P/V group patients might have
delayed detection of an infection, resulting in further pro-
gression and greater consequence. Moreover, it should be
considered that full-dose study drug administration was
continued for a 2-week period in all P/V group patients,
regardless of their need for analgesics, which might have
contributed to increased susceptibility to or delayed recog-
nition of infection. Regardless of mechanism, these safety
issues merit careful consideration because of the importance
of sternal complications in this setting, not only for
NSAIDS and COX-2 inhibitors but also for any new med-
ication that can impair normal inflammatory reparative pro-
cesses.
Second, the incidence of both cardiovascular and cere-
brovascular SAEs was proportionally, but not significantly,
greater in P/V group patients than in control patients, po-
tentially implicating a thrombosis-mediated association
with COX-2 inhibitor use.28 Nearly all of our patients un-
derwent cardiac surgery with cardiopulmonary bypass and
hypothermia. In such patients the delicate balance between
platelets, endothelial cells, and serum clotting factors is
disturbed, with a consequent thrombosis and clot lysis oc-
curring disparately and unpredictably throughout the vascu-
lar system. Given that COX-2 inhibitors are platelet sparing,
they might tip the balance toward thrombosis during periods
of platelet activation. In addition, it has been argued that
because COX-1 is unaffected, consequent release of throm-
boxane A2 further promotes platelet activation and throm-
bosis. Of note are 3 recently published analyses addressing
this issue in chronically treated patients with arthritis.28,29
The first28 contrasted the results of the CLASS (celecoxib)
and VIGOR (rofecoxib) clinical trials, with historical con-
trols derived from the aspirin trials. Using a summary sta-
tistic, the authors emphasized the potential association be-
tween COX-2 inhibition and thrombogenic events
(myocardial infarction, stroke, and vascular death). The
second,29 in contrast, addressed a meta-analysis involving
patients with both osteoarthritis and rheumatoid arthritis
with respect to the use of rofecoxib versus placebo versus
ibuprofen or diclofenac, finding no significant association
among these groups for vascular events. In addition, a
separate analysis of the CLASS study data found no in-
creased risk of serious cardiovascular thrombotic events
associated with celecoxib compared with naproxen and ibu-
profen.30 Given that 4 of the 5 infarctions in this trial
occurred perioperatively (ie, in close proximity to the ad-
ministration of the first intravenous parecoxib/valdecoxib
dose), if an association is inferred, then the acute intrave-
nous administration of a COX-2 inhibitor must precipitate
coronary artery thrombosis acutely (a hypothesis similar to
that proposed by the recent work of Mukherjee et al28).
On the other hand, any extrapolation of the above
chronic treatment regimens to treatment of acute pain in the
perioperative setting must be made cautiously. Furthermore,
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it must be understood that arterial thrombosis after surgical
revascularization might be precipitated by a number of other
phenomena, including28,31-36 mechanically induced endo-
vascular injury; acute reversal of heparin, precipitously in-
creasing serum thrombin levels; concomitant use of antifi-
brinolytic agents (eg, aprotinin or episolon aminocaproic
acid) to mitigate hemorrhage; instigation of a generalized
inflammatory response, leading to platelet activation; and
centralization of activated platelets. All are operative here,
making it difficult if not impossible to discern an indepen-
dent association between the study drug and thrombosis in
our trial of a limited sample size. However, perhaps because
patients likely received such aspirin not immediately on
reperfusion but rather hours later, substantial platelet acti-
vation might have already occurred and precipitated a cas-
cade leading to myocardial infarction and stroke.39 The
observation that 4 of the 5 myocardial infarction events
occurred within the immediate perioperative period is con-
sistent with this hypothesis. Clearly, resolution of this im-
portant issue is necessary, particularly for higher-risk pa-
tients, such as ours.
Third, regarding the interaction between antifibrinolytic
therapy use and COX-2 inhibitors, we found the following.
Of the 311 patients receiving COX-2 inhibitors, 193 (62%)
also received antifibrinolytic therapy, and of these, 4 had
either pulmonary embolism, myocardial infarction, throm-
bophlebitis, or arterial dissection versus 1, 4, 2, and 0
patients, respectively, who received COX-2 inhibitors but
did not receive antifibrinolytics. For the control group, one
patient who received antifibrinolytics had one of these 4
complications versus no patients among those not receiving
antifibrinolytics. Although there is no evidence of interac-
tion, the numbers are small, and their significance must be
assessed in a larger trial.
Fourth, the incidence of renal insufficiency in P/V group
patients was proportionally greater than that for control
patients, although the incidence of increased renal function
test parameters was equal. Both COX-2 and COX-1 inhibi-
tion can be associated with impaired renal function.9 Given
that even renal dysfunction without failure is associated
with reduced survival and increased cost in these patients16
and given the possibility of a type I error, then the signifi-
cance of this safety observation remains unresolved.
Finally, as with any new therapy, the cost-effectiveness
must be assessed if the therapy has been proved effective
and safe, and we will address such separately in the next
trial.
Limitations of the Current Study
There are several limitations to the present study. First, our
trial was marginally powered (68%) to detect a 2-fold
difference (20% vs 10%) in SAEs between study groups and
was not powered (6%) to detect differences for specific
SAEs. Moreover, the incidence of the SAEs in the control
group patients was considerably lower than expected when
compared with that reported in large-scale studies and clin-
ical trials among similar patients (6% for Q-wave infarction,
3% for stroke, and 7% for renal dysfunction).16,17,37 Conse-
quently, a larger trial with equal numbers of patients in each
treatment group is necessary to resolve these safety findings.
Second, several potentially important outcomes were not
measured, such as chest tube output in the first 24 to 48
postoperative hours. Use of agents that are platelet sparing,
such as COX-2 inhibitors, might mitigate blood loss in these
patients, an effect not assessed in our trial.
Third, the control group actually received a nearly ideal
standard of care (ie, analgesia in this clinical trial), given
that they had ready access to morphine PCA and were
closely observed for management of pain. Such a standard
might be difficult to achieve in practice, especially given
current efforts to limit postoperative resources. Conse-
quently, one might speculate that even greater benefit can be
realized with parecoxib/valdecoxib, given their ease of use.
Fourth, only a single dosage regimen and duration of
parecoxib/valdecoxib was assessed. Considering that lower
doses of parecoxib and valdecoxib also have been shown
effective,4-6,38 then the potential to achieve the desired an-
algesic benefits with possibly lower risk of AEs with lower
doses, shorter periods of administration, or both needs to be
explored with future studies.
Fifth, we did not include a group receiving nonspecific
NSAID agents, and therefore comparisons with such drugs
in these patients cannot be surmised.
Sixth, regarding generalization, as for any clinical trial,
inclusion and exclusion criteria can impose rather strict
limits. Here, we estimate that our findings would be strictly
applicable to approximately 220,000 patients or 30% of
patients undergoing CABG with cardiopulmonary bypass
annually throughout the world. Therefore caution should be
exercised in the application of these findings to the entire
CABG surgery population.
Finally, because of issues raised here, a follow-up trial
should be designed to provide greater insight into the safety
concerns and efficacy benefits in this population. In view of
the limited power of this study, a larger trial will be needed
to address relative frequency of uncommon events that
might be associated with parecoxib/valdecoxib therapy.
Conclusion
The intravenous-oral parecoxib/valdecoxib regimen demon-
strated superiority for pain relief over an aggressive thera-
peutic regimen supplemented with PCA. However, the
higher incidence of SAEs observed with the parecoxib/
valdecoxib regimen, as well as the higher incidence of
sternal infections, raise important concerns and mandate
comprehensive evaluation in a large-scale trial before use in
patients undergoing CABG surgery.
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The cohort of the McSPI Research Group, who participated in this
study. These investigators are listed in alphabetical order with their
medical centers.
Keith Allen, MD, St Vincent Hospital, Indianapolis, Ind
Peter Alston, MD, Royal Infirmary, Edinburgh, Scotland
Prasad Atluri, MD, VA Medical Center, Houston, Tex
Elliott Bennett-Guerrero, MD, Columbia Presbyterian Medical
Center, New York, NY
Steven Boyce, MD, Washington Hospital Center, Silver Spring,
Md
David Bronheim, MD, The Mt Sinai Medical Center, New York,
NY
Edward Busse, MD, Regina General Hospital, Regina, Canada
Jean Bussieres, MD, Laval Hospital, Sainte-Foye, Canada
Marguerita Camacho, MD, Montefiore Medical Center, Bronx,
NY
Maria Chakerian, MD, Bay Area Center for Pain & Palliative Care,
Los Gatos, Calif
Davy Cheng, MD, Toronto General Hospital, Toronto, Canada
Colm Cole, MD, St Paul’s Hospital, Vancouver, Canada
Paul Dlabal, MD, Cycle Solutions, Inc, Austin, Tex
Roger Dreiling, MD, Corvalis Clinic, Corvalis, Ore
Peter Duke, MD, University of Manitoba, Winnipeg, Canada
Jean-Yves Dupuis, MD, University of Ottawa Heart Institute,
Ottawa, Canada
Michael Eaton, MD, University of Rochester Medical Center,
Rochester, NY
Jeffrey Everett, MD, University of Iowa, Iowa City, Iowa
Rob Feneck, MD, St Thomas Hospital, London, United Kingdom
Andreas Fiehn, MD, Klinikum Kassel, Kassel, Germany
Barry Finnegan, MD, University of Alberta, Edmonton, Canada
Michael Fiocco, MD, Union Memorial Hospital, Silver Spring, Md
Jane Fitch, MD, Baylor College of Medicine, Houston, Tex
Manuel Fontes, MD, New York Presbyterian (Cornell), New York,
NY
Mark Fox, MD, Cardiothoracic Centre, Liverpool, United King-
dom
Susan Garwood, MD, Yale University, New Haven, Conn
George Gordon, MD, New England Medical Center, Boston, Mass
Michael Grave, MD, Long Island Jewish Hospital, New Hyde
Park, NY
Richard Hall, MD, QE II Health Sciences Center, Halifax, Canada
Kenneth Hanger, MD, Roper Care Alliance Hospital, Mt Pleasant,
SC
Charles Hantler, MD, University of Texas Health Sciences Center,
San Antonio, Tex
Gunter Hempelmann, MD, Justus-Liebig University, Giessen,
Germany
William Higgs, MD, Gulf Coast Clinical Services, Inc, Mobile,
Ala
Andreas Hoeft, MD, University of Bonn, Bonn, Germany
Charles Hogue, MD, Washington University, St Louis, Mo
Mitchell Jacobs, MD, North Shore University Hospital, Manhas-
set, NY
Shubjeet Kaur, MD, University of Massachusetts Memorial Health
Center, Worcester, Mass
Hurley Knott, MD, SORRA Research, Birmingham, Ala
Dan Kopacz, MD, Virginia Mason Medical Center, Seattle, Wash
Michael Koren, MD, Jacksonville Center for Clinical Research,
Jacksonville, Fla
John Laschinger, MD, Sinai Hospital of Baltimore, Silver Spring,
Md
John Leslie, MD, Mayo Clinic Hospital, Phoenix, Ariz
Stephen Lincoln, MD, St Joseph’s Medical Center, Silver Spring,
Md
Phil Malan, MD, University of Arizona, Tucson, Ariz
Eike Martin, MD, University of Heidelberg, Heidelberg, Germany
Raymond Martineau, MD, Montreal Heart Institute, Montreal,
Canada
Joseph Mathew, MD, Duke University Medical Center, Durham,
NC
David Mazer, MD, St Michael’s Hospital, Toronto, Canada
Richard McLean, MD, Hamilton Health Sciences Corp, Hamilton,
Canada
Stan Mogelnicki, MD, St Joseph’s Hospital, Atlanta, Ga
Chris Mora Mangano, MD, Stanford University Medical Center,
Stanford, Calif
Lars Newsome, MD, Scripps Memorial Hospital, La Jolla, Calif
Nancy Nussmeier, MD, Texas Heart Institute, Houston, Tex
Elisabeth Ott, MD, University of Munich, Munich, Germany
James Park, MBChB, South Cleveland Hospital, Middlesbrough,
United Kingdom
Eric Pierce, MD, Boston University Medical Center, Boston, Mass
Evan Pivalizza, MD, Hermann Hospital, University of Houston,
Houston, Tex
Joseph Quinlan, MD, University of Pittsburgh, Pittsburgh, Pa
Fiona Ralley, MD, University of Western Ontario, London, Can-
ada
James Ramsay, MD, Emory University Hospital, Atlanta, Ga
Lowell Reynolds, MD, Center for Pain Management, Loma Linda
Medical Center, Loma Linda, Calif
Gary Roach, MD, Kaiser Foundation Hospital, San Francisco,
Calif
Louis Samuels, MD, Hahnemann University Hospital, Philadel-
phia, Pa
Jens Scholz, MD, University Hospital Eppendorf, Hamburg, Ger-
many
Ketan Shevde, MD, Maimonides Medical Center, Brooklyn, NY
David Smith, MD, Southhampton General Hospital, Southhamp-
ton, United Kingdom
Hans Sonntag, MD, University of Goettingen, Goettingen, Ger-
many
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Bruce Spiess, MD, Medical College of Virginia, Richmond, Va
Ethan Stein, MD, Mary Washington Hospital, Silver Spring, Md
Louis Suarez, MD, Appleton Medical Center, Appleton, Wis
Steven Timmis, MD, William Beaumont Hospital, Royal Oak, Mich
James Todd, MD, Peninsula Regional Medical Center, Silver
Spring, Md
Bruce Toporoff, MD, Southwest Clinical Research, Inc, Phoenix,
Ariz
Mark Trankina, MD, Shands Hospital University of Florida,
Gainesville, Fla
Hamed Umedaly, MD, University of British Columbia, Vancou-
ver, Canada
Hugo Van Aken, MD, University of Muenster, Muenster, Germany
Joseph Van DeWater, MD, Medical Center of Central Georgia,
Macon, Ga
Eugene Viscusi, MD, Thomas Jefferson University Hospital, Phil-
adelphia, Pa
Timothy Votapka, MD, Evanston Northwestern Healthcare, Evan-
ston, Ill
Alain Vuylsteke, MD. Papworth Hospital NHS Trust, Cambridge,
United Kingdom
Mark Wallace, MD, University of California, San Diego, La Jolla,
Calif
Herb Ward, MD, VA Medical Center Surgical Services, Minne-
apolis, Minn
David Whitaker, MD, Manchester Royal Infirmary, Manchester,
United Kingdom
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